Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CGEN vs VCYT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CGEN Captures Overall Composite Edge (47.1 HOLD vs 48.0 HOLD), While VCYT Leads 4–2 on Growth & Valuation Pillars
CGEN Overall Winner
6-Pillar Tally: CGEN 2 – 4 VCYT
Matrix Metrics: CGEN 8 – 2 VCYT
As of Nov 17, 2026, Compugen Ltd (CGEN) captures the overall head-to-head institutional edge over Veracyte, Inc. (VCYT) on higher Unified Composite conviction (47.1/100 HOLD vs. 48.0/100 HOLD) after splitting the core matrix 8–2 (led by Valuation Multiples, Profitability & Quality), while VCYT wins 4–2 across the 6-pillar growth and valuation breakdown. CGEN trades at $2.02 (12.4x Forward P/E, 41.3% operating margin) versus VCYT at $24.23 (15.3x Forward P/E, 15.0% operating margin).
- Composite vs. Pillar Nuance: While VCYT currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 15.0% operating margin) and revenue trajectory (+102.1% vs. +15.1% YoY).
- Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CGEN vs VCYT
CGEN
Head-to-Head Winner
Compugen Ltd
$2.02
-0.98% 1D
Market Cap
$198.9M
TTM Revenue
$76M
Forward P/E
12.4x
Beta / 30D Vol
1.44β · 62% Vol
Unified Composite Score
47.1
HOLD
Tech 44.0
Fund 52.0
Flow 54.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
VCYT
Veracyte, Inc.
$24.23
+0.92% 1D
Market Cap
$2.0B
TTM Revenue
$582M
Forward P/E
15.3x
Beta / 30D Vol
2.98β · 194% Vol
Unified Composite Score
48.0
HOLD
Tech 55.0
Fund 56.0
Flow 57.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (CGEN 2 – 4 VCYT)
1. Valuation Multiples
CGEN
Forward P/E
12.4x
15.3x
Trailing P/E
5.4x
15.8x
PEG Ratio
1.29x
N/M
EV / Revenue
2.6x
3.1x
2. Growth & Scale
VCYT
Revenue Growth (YoY)
+102.1%
+15.1%
Earnings Growth (YoY)
+0.0%
+58.3%
TTM Revenue (USD)
$76M
$582M
Market Cap
$198.9M
$2.0B
3. Profitability & Quality
CGEN
Gross Margin
86.2%
74.2%
Operating Margin
41.3%
15.0%
Net Profit Margin
47.9%
21.8%
Return on Equity (ROE)
57.2%
9.4%
4. Balance Sheet & Cash Flow
VCYT
Cash Generation (TTM)
$32M EBITDA
$162M
Cash Flow Margin
41.9% EBITDA Mgn
27.8%
Net Cash / Leverage
$4.3M Net Cash
$159M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
VCYT
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
89.7% (57th %ile)
197.3% (47th %ile)
Put/Call OI Skew
N/A
27.31x (Put-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
VCYT
OpEx & R&D Intensity
44.9% of Rev ($34M)
59.2% of Rev ($344M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
High-Margin Pricing Power Moat
Scale & Operating Efficiency Moat
Supply-Chain Role
Biotechnology Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CGEN (8) vs VCYT (2)| Institutional Metric | CGEN | VCYT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $198.9M | $2.0B | VCYT | |
| Trailing P/E Ratio | 5.4x | 15.8x | CGEN | |
| Forward P/E Ratio | 12.4x | 15.3x | CGEN | |
| Revenue Growth (YoY) | +102.1% | +15.1% | CGEN | |
| Operating Margin (TTM) | 41.3% | 15.0% | CGEN | |
| Net Profit Margin | 47.9% | 21.8% | CGEN | |
| Return on Equity (ROE) | 57.2% | 9.4% | CGEN | |
| 52-Week Range Position | 33% ($1–$3) | 6% ($22–$61) | CGEN | |
| Beta / 30D Volatility | 1.44β · 62% Vol | 2.98β · 194% Vol | CGEN | |
| Unified Institutional Score | 47.1 / 100 (HOLD) | 48.0 / 100 (HOLD) | VCYT | |
| Trailing 12M Revenue (USD) | $76M | $582M | Scale | |
| Gross Profit Margin (TTM) | 86.2% | 74.2% | Quality | |
| PEG Ratio & EV / Revenue | 1.29x PEG · 2.6x EV/Rev | N/M PEG · 3.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $32M EBITDA ($4.3M Net Cash) | $162M ($159M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CGEN +47.22 pp
3M Horizon
CGEN +25.36 pp
6M Horizon
CGEN +15.87 pp
1Y Horizon
CGEN +61.59 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CGEN Revenue | VCYT Revenue | CGEN Op. Margin | VCYT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $20M | $90M | -130.5% | -24.2% | VCYT |
| FY2019 | N/A | $120M | N/A | -12.6% | VCYT |
| FY2020 | $0M | $120M | -1574.8% | -30.1% | VCYT |
| FY2021 | $10M | $220M | -584.6% | -37.3% | VCYT |
| FY2022 | $10M | $300M | -471.7% | -13.9% | VCYT |
| FY2023 | $30M | $360M | -38.8% | -23.8% | VCYT |
| FY2024 | $30M | $450M | -53.4% | 3.6% | VCYT |
| FY2025 | $70M | $520M | 43.1% | 11.2% | CGEN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CGEN
BREAKDOWN
Current IV
89.7%
IV Percentile
57th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
VCYT
BREAKDOWN
Current IV
197.3%
IV Percentile
47th %ile
Put/Call OI Skew
27.31x (Put-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CGEN Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
44.9% of Rev ($34M)
90D Engineering Disclosures
0 Published
VCYT Moat Profile
Scale & Operating Efficiency Moat
Diagnostics & Research Operator
OpEx & R&D Reinvestment
59.2% of Rev ($344M)
90D Engineering Disclosures
0 Published
Investor FAQ CGEN vs VCYT Key Questions & Quantitative Answers
As of Nov 17, 2026, Compugen Ltd (CGEN) captures the overall head-to-head institutional edge over Veracyte, Inc. (VCYT) on higher Unified Composite conviction (47.1/100 HOLD vs. 48.0/100 HOLD) after splitting the core matrix 8–2 (led by Valuation Multiples, Profitability & Quality), while VCYT wins 4–2 across the 6-pillar growth and valuation breakdown. CGEN trades at $2.02 (12.4x Forward P/E, 41.3% operating margin) versus VCYT at $24.23 (15.3x Forward P/E, 15.0% operating margin). Composite vs. Pillar Nuance: While VCYT currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 15.0% operating margin) and revenue trajectory (+102.1% vs. +15.1% YoY). Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VCYT leads the Growth & Scale pillar: CGEN posts +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin), compared with VCYT at +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGEN cumulative revenue shifted +250.0% while VCYT shifted +477.8%. In operating R&D and SG&A reinvestment, CGEN deploys 44.9% of Rev ($34M) (0 90-day corporate R&D disclosures) versus 59.2% of Rev ($344M) (0 disclosures) for VCYT.
CGEN screens cheaper on headline valuation multiples. CGEN trades at 12.4x Forward P/E, 5.4x Trailing P/E, 1.29x PEG, and 2.6x EV/Revenue (41.9% EBITDA margin), whereas VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEN (57.2% ROE) versus VCYT (9.4% ROE) capital efficiency.
In options market volatility and institutional positioning, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk). By comparison, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 27.31x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.98β · 194% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
VCYT vs CGEN · Reverse Pair
VCYT vs CDNA
· Sector Peer
VCYT vs TWST
· Sector Peer
VCYT vs TXG
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking